Shares of Impax Laboratories Inc (NASDAQ:IPXL) have been given an average recommendation of “Hold” by the eighteen analysts that are covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating and five have issued a buy rating on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $19.41.
A number of analysts recently issued reports on IPXL shares. Cantor Fitzgerald set a $35.00 price objective on Impax Laboratories and gave the stock a “buy” rating in a research report on Friday, December 15th. Cowen restated a “hold” rating and set a $16.00 target price on shares of Impax Laboratories in a report on Friday, November 10th. Leerink Swann assumed coverage on Impax Laboratories in a report on Tuesday, January 2nd. They set an “outperform” rating and a $22.00 target price for the company. UBS Group raised their target price on Impax Laboratories from $12.00 to $16.00 and gave the company a “sell” rating in a report on Monday, October 30th. Finally, Zacks Investment Research upgraded Impax Laboratories from a “strong sell” rating to a “hold” rating in a report on Monday, January 15th.
Shares of Impax Laboratories (NASDAQ:IPXL) traded up $0.30 during trading hours on Tuesday, hitting $19.40. The company had a trading volume of 722,900 shares, compared to its average volume of 915,014. The company has a quick ratio of 1.32, a current ratio of 1.81 and a debt-to-equity ratio of 1.59. The firm has a market cap of $1,414.39, a P/E ratio of 28.09, a price-to-earnings-growth ratio of 0.95 and a beta of 1.11. Impax Laboratories has a 1 year low of $7.75 and a 1 year high of $25.70.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Public Employees Retirement System of Ohio raised its position in shares of Impax Laboratories by 12.7% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 6,911 shares of the specialty pharmaceutical company’s stock worth $111,000 after acquiring an additional 780 shares in the last quarter. Amalgamated Bank acquired a new stake in shares of Impax Laboratories during the 3rd quarter worth about $201,000. Stevens Capital Management LP acquired a new stake in shares of Impax Laboratories during the 3rd quarter worth about $203,000. Quantbot Technologies LP raised its position in shares of Impax Laboratories by 279.0% during the 3rd quarter. Quantbot Technologies LP now owns 10,031 shares of the specialty pharmaceutical company’s stock worth $203,000 after acquiring an additional 7,384 shares in the last quarter. Finally, Advisory Services Network LLC acquired a new stake in shares of Impax Laboratories during the 2nd quarter worth about $207,000. Institutional investors and hedge funds own 91.46% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Impax Laboratories Inc (IPXL) Receives $19.41 Consensus Price Target from Analysts” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another site, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/02/16/impax-laboratories-inc-ipxl-receives-19-41-consensus-price-target-from-analysts.html.
About Impax Laboratories
Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.
Receive News & Ratings for Impax Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.